Icatibant Teva (Icatibant Acetate)

Icatibant acetate acts as a selective antagonist of the bradykinin B2 receptor. By blocking this receptor, it prevents bradykinin‑mediated vasodilation and increased vascular permeability, which are the primary drivers of edema in hereditary angioedema.

The prescribed dose is determined by the treating physician based on the patient’s condition and clinical guidelines. In practice, a single 30 mg subcutaneous injection is commonly administered for an acute attack, but exact dosing and repeat administration are at the prescriber’s discretion.

Safety data for Icatibant acetate in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

The primary alternative for hereditary angioedema is plasma‑derived or recombinant C1‑esterase inhibitor replacement. Icatibant works by blocking bradykinin receptors, offering a rapid, subcutaneous option, whereas C1‑esterase inhibitors replace the deficient protein and are administered intravenously. Choice depends on patient preference, attack severity and clinical response.

Icatibant Teva must be stored refrigerated at 2 °C to 8 °C. Keep the prefilled syringes in the original packaging, protect them from light, and avoid freezing or shaking the product. If temporary temperature excursions occur, consult the product label before use.

The medication is supplied as a prefilled syringe containing 30 mg of icatibant acetate in 0.3 mL. After cleaning the injection site, the syringe is inserted subcutaneously, typically into the abdomen or thigh, and the plunger is depressed to deliver the full dose. Patients should be observed for any immediate reactions.

Serious adverse events include hypersensitivity reactions such as rash, urticaria, or anaphylaxis, severe abdominal pain, and rare cases of thrombocytopenia. Any signs of a severe allergic response or unexplained intense pain should prompt immediate medical evaluation.

Icatibant Teva is contraindicated in individuals with known hypersensitivity to icatibant acetate or any of the formulation excipients. Caution is also advised for patients with a history of severe allergic reactions, and it should be used under medical supervision in those with uncontrolled cardiovascular disease.